Overexpression of BDNF and/or TrkB has been observed in a variety of tumors, including neuroblastoma, lung, breast, stomach, colorectal and head and neck cancers, and shown to promote tumor cell proliferation, survival, epithelial-mesenchymal transition, invasiveness, and drug resistance as well as angiogenesis [89–93]. Here, NTRK2 is linked to neuroblastoma.